The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis.

In addition, it improves fatty liver.

Reduction of the risk of fatty liver syndrome

The use of the said strain is particularly effective in the prevention/treatment of hepatic steatosis (fatty liver) and in nonalcoholic hepatic steatosis.

There are two major types of steatohepatitis: non-alcoholic and alcoholic.

Hepatic steatosis - When fat builds up in the liver - Diagnosing steatosis at an early stage.

Is NAFLD or non-alcoholic fatty liver disease in kids reversible?

A composition is provided for improving fatty liver.

The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject.

The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH).

Disclosed is a medicament for preventing or treating fatty liver.

The object is to diagnose the presence or absence of the occurrence of a fatty liver disease, the degree of progression of a fatty liver disease or the like in a simpler manner compared with conventional liver biopsies.

Tests revealed that she had non-alcoholic steatohepatitis, the most severe form of non-alcoholic fatty liver disease.

Disclosed are: a method for determining the occurrence of progressive non-alcoholic steatohepatitis; and a method for determining the occurrence of hepatic fibrosis in non-alcoholic fatty liver disease.

Of those with a clinical diagnosis of fatty liver disease (a high level of steatosis, greater than 5.2%), 68% did not have fatty liver disease at the end of 24 weeks follow up.